Cardiac function in mice lacking the glucagon-like peptide-1 receptor

被引:159
|
作者
Gros, R
You, XM
Baggio, LL
Kabir, MG
Sadi, AM
Mungrue, IN
Parker, TG
Huang, QL
Drucker, DJ
Husain, M
机构
[1] Toronto Gen Hosp, Res Inst, Div Cellular & Mol Biol, Toronto, ON M5G 2C4, Canada
[2] Univ Toronto, Heart & Stroke Richard Lewar Ctr Excellence, Toronto, ON M5G 2C4, Canada
[3] Univ Toronto, Toronto Gen Hosp, Dept Med, Banting & Best Diabet Ctr, Toronto, ON M5G 2C4, Canada
关键词
D O I
10.1210/en.2003-0007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Glucagon-like peptide-1 (GLP-1) acts via its G protein-coupled receptor (GLP-1R) to regulate blood glucose. Although the GLP-1R is widely expressed in peripheral tissues, including the heart, and exogenous GLP-1 administration increases heart rate and blood pressure in rodents, the physiological importance of GLP-1R action in the cardiovascular system remains unclear. We now show that 2-month-old mice with genetic deletion of the GLP-1R (GLP-1R(-/-)) exhibit reduced resting heart rate and elevated left ventricular (LV) end diastolic pressure compared with CD-1 wild-type controls. At the age of 5 months, echocardiography and histology demonstrate increased LV thickness in GLP-1R(-/-) mice. Although baseline hemodynamic parameters of GLP-1R(-/-) did not differ significantly from those of wild type, GLP-1R(-/-) mice displayed impaired LV contractility and diastolic function after insulin administration. The defective cardiovascular response to insulin was not attributable to a generalized defect in the stress response, because GLP-1R(-/-) mice responded appropriately to insulin with increased c-fos expression in the hypothalamus and increased circulating levels of glucagon and epinephrine. Furthermore, LV contractility after exogenous epinephrine infusion was also reduced in GLP-1R(-/-) mice. These findings provide new evidence implicating an essential role for GLP-1R in the control of murine cardiac structure and function in vivo.
引用
收藏
页码:2242 / 2252
页数:11
相关论文
共 50 条
  • [31] Glucagon-like peptide-1 and satiety
    S. R. Bloom
    Nature, 1997, 385 : 214 - 214
  • [32] Glucagon-Like Peptide-1 and Diabetes
    Monami, Matteo
    EXPERIMENTAL DIABETES RESEARCH, 2011,
  • [33] Glucagon-like peptide-1 and satiety
    van, Dijk, G.
    Thiele, T.E.
    Seeley, R.J.
    Woods, S.C.
    Bernstein, I.L.
    Bloom, S.R.
    Nature, 1997, 385 (6613)
  • [34] Glucagon-like peptide-1 and satiety
    G. van Dijk
    T. E. Thiele
    R. J. Seeley
    S. C. Woods
    I. L. Bernstein
    Nature, 1997, 385 : 214 - 214
  • [35] Is Glucagon-like peptide-1 for real?
    Murr, Michel M.
    SURGERY FOR OBESITY AND RELATED DISEASES, 2014, 10 (05) : 786 - 786
  • [36] Glucagon-Like Peptide-1 Agonists
    Stanton, Eloise W.
    Manasyan, Artur
    Banerjee, Rakhi
    Hong, Kurt
    Koesters, Emma
    Daar, David A.
    ANNALS OF PLASTIC SURGERY, 2025, 94 (01) : 121 - 127
  • [37] Glucagon-like peptide-1 agonists
    Padwal, Raj
    BMJ-BRITISH MEDICAL JOURNAL, 2012, 344
  • [38] INSULINOTROPIC ACTION OF TRUNCATED GLUCAGON-LIKE PEPTIDE-1 IN MICE
    AHREN, B
    ACTA PHYSIOLOGICA SCANDINAVICA, 1995, 153 (02): : 205 - 206
  • [39] NEPHROPROTECTIVE POTENTIAL OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS
    Shamhalova, Minara S.
    Sklyanik, Igor A.
    Shestakova, Marina V.
    DIABETES MELLITUS, 2020, 23 (01): : 56 - 64
  • [40] Signal transduction and desensitization of the glucagon-like peptide-1 receptor
    Thorens, B
    Widmann, C
    ACTA PHYSIOLOGICA SCANDINAVICA, 1996, 157 (03): : 317 - 319